||COM SHS NPV
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Ondine Biomed Share Discussion Threads
Showing 1 to 6 of 25 messages
Chat Pages: 1
|There is a film called Ondine out now. This is why the share has gone up|
|Ondine Biopharma Cor Ondine Bio preclinical tests show photodisinfection effective vs hospital bug
LONDON (Thomson Financial) - Ondine Biopharma Corporation said its
photodisinfection technology has shown a high level of effectiveness in
preclinical trials against Pseudomonas aeruginosa, one of the most dangerous
Ondine says the work provides important preclinical support for its
photodisinfection programs for skin wounds, burns and outer ear infections.
Nicolas Loebel, chief technology officer, said: "Pseudomonas is extremely
difficult to kill and occurs throughout hospital environments as an
opportunistic pathogen. Our photodisinfection system has demonstrated 100 pct
eradication of Pseudomonas aeruginosa in planktonic (free-floating) cultures,
and in excess of 99.9 pct kills in biofilms.
"The data from the preclinical research supports our belief that our
photodisinfection technology could provide significant benefits over
conventional antipseudomonal therapies such as topical antibiotics or micronized
silver," he said.
"After launching Periowave, our ground-breaking photodisinfection treatment
for adult periodontal disease, our new product development efforts are being
focused into nasal MRSA decolonization, disinfection of skin wounds and burns
and treatment of external ear infections. The combination of wide therapeutic
window, absence of resistance and treatment speed implies a potentially new
paradigm in the treatment of these complex infections," he said.
|University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology http://www.investegate.co.uk/Article.aspx?id=20071009120000P13E9|
|Just for info'
|Price at start of thread 84.5p|
|Ondine Biopharma Corporation (OBC) is a biopharmaceutical company focused on the commercial development of a laser-activated, non-antibiotic treatment for intraoral bacterial infections. OBC maintains corporate offices in Vancouver, Canada and Redmond Washington.
The antibacterial technology was developed and patented by the Eastman Dental Institute, University College London (UCL). OBC acquired patent rights in 1999 and intends to complete both EU and US clinical trials prior to introduction of the product to periodontists and general dentists. OBC's has access to world-class microbiology facilities and expertise at three major Universities for development of further indications and expansion of the product pipeline.|
Chat Pages: 1